Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Inclusion Criteria:

Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib
Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy
Have adequate organ function

Exclusion Criteria:

Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor
Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds